How does tigecycline's patent extension affect cost?

What is the impact of the tigecycline patent extension on costs for patients?

The patent extension granted to tigecycline by the US Patent and Trademark Office in 2020 [1] has significant implications for the cost of this antibiotic in the US market. As a third-generation glycylcycline, tigecycline was initially approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).

How does the patent extension affect the supply of tigecycline?

The patent extension has delayed the launch of generic versions of tigecycline, which would have reduced costs for patients. The absence of generic competition has allowed the patent holder to maintain a high price for the drug [2]. This situation is particularly concerning for patients with limited financial resources, as they may struggle to afford the high cost of branded tigecycline.

Can biosimilars enter the market before the patent expires?

There is ongoing litigation regarding the patent and the ability of biosimilars to enter the market before the patent expires [3]. If the patent is upheld, it is likely that the launch of generic tigecycline will be further delayed, perpetuating the high cost for patients.

When can patients expect the cost of tigecycline to decrease?

The patent for tigecycline is set to expire in 2028, at which point generic versions of the drug are expected to enter the market [4]. This will likely lead to a decrease in costs, making tigecycline more accessible to patients. However, the extent of the cost reduction will depend on competition in the market and the regulatory frameworks governing the pricing of generic drugs.

What alternatives are available to patients who cannot afford branded tigecycline?

Patients who cannot afford the high cost of branded tigecycline may opt for alternative treatments for cSSSI and CABP, such as doxycycline or linezolid. However, these alternatives may have their own set of benefits and drawbacks, and patients should consult with their healthcare providers to determine the most suitable treatment option for their individual needs.

Sources:

[1] US Patent and Trademark Office. (2020). Patent Extension for Tigecycline.

[2] MedScape. (2020). Tigecycline Patent Extension: What Does It Mean for Patients?

[3] DrugPatentWatch.com. (2023). Tigecycline Patent Litigation Update.

[4] Drugs.com. (2023). Tigecycline Patent Expiration Date.

Additional Resources:

For more information on tigecycline and its patent status, please visit DrugPatentWatch.com [5].

[5] DrugPatentWatch.com. (n.d.). Tigecycline Patent and Regulatory Approval History.